Innovative technology-transcatheter aortic valve implantation: Cost and reimbursement issues

Abstract

Objective. Transcatheter aortic valve implantation (TAVI) offers a new treatment option for patients with severe symptomatic aortic valve stenosis, classified as “inoperable”. The purpose of the study was to reveal the association between ascertained hospital costs with the actual patient Diagnosis-Related Group (DRG). Method. We examined 50 consecutive patients who underwent either transapical TAVI, (TAVI-TA) or transfemoral TAVI (TAVI-TF) with the Edwards SAPIEN valve and CoreValve^® between September 2009 and August 2011. Results. Fourty-nine patients had successful valve deployment. Seven patients died within 30 days of the operation. The mean length of hospital stay for TAVI-TA was 199 hours (range 77–362), and the mean costs for TAVI-TA were 55,690 US$. For TAVI-TF the mean length of hospital stay was 170 hours (range 49–276) and the mean costs were 52,087 US$. Conclusion. There was no significant difference between TAVI-TA and TAVI-TF patient characteristics. There was a significant discrepancy between actual hospital costs and the current Norwegian DRG reimbursement for the TAVI procedure. This discrepancy can be partly explained by excessive costs related to the introduction of a new program with new technology. Costly innovations should be considered in price-setting of reimbursement for novel technology.

Key words::

• (Innovative technology)
• Transcatheter aortic valve implantation
• hospital cost
• DRG reimbursement
• cost analysis

Acknowledgements

The authors acknowledge the contribution of nursing staff at the Department of Cardiothoracic Surgery, and Department of Cardiology and Intervention Center at Rikshospitalet Oslo University Hospital.

Declaration of interest: The authors report no conflicts of interest. The authors alone are responsible for the content and writing of the article.